Recruiting PHASE3 INTERVENTIONAL 1-arm NCT04706910

18F-DOPA II - PET Imaging Optimization

Sponsor: University of Alberta

Conditions Brain Tumor Congenital Hyperinsulinism Lewy Body Disease Neuroblastoma Neuroendocrine Tumors Parkinson Disease

Interventions 18F-DOPA Furosemide Injection

Updated 9 times since 2021 Last updated: Feb 4, 2026 Started: Jan 20, 2021 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Brain Tumor and Congenital Hyperinsulinism and is currently actively recruiting participants. University of Alberta leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Jun 2025 — Feb 2026 [monthly]

Recruiting PHASE3
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Recruiting PHASE3

▶ Show 4 earlier versions

May 2023 — May 2024 [monthly]

Recruiting PHASE3
May 2022 — May 2023 [monthly]

Recruiting PHASE3
Mar 2021 — May 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Feb 2021 — Mar 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Alberta

Data source: University of Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada